GLP-1 Non-Responders: What the Science Says and What to Do Next

The Non-Response Spectrum

Not every plateau is the same. There's a spectrum from "not yet at therapeutic dose" to "genuine genetic resistance," and most patients are closer to the first end.

Level 1: Premature Plateau (Most Common)

You started a GLP-1, lost some weight in the first month, then stalled. Most likely cause: you haven't reached a therapeutic dose yet. Semaglutide titration takes 16–20 weeks. Tirzepatide takes 12–20 weeks. Weight loss typically accelerates at moderate-to-high doses.

Level 2: Dose-Appropriate Plateau

You've been at a therapeutic dose (1.0mg+ semaglutide or 5.0mg+ tirzepatide) for 12+ weeks and loss has stalled. Possible causes: caloric compensation, medication interactions, thyroid dysfunction, metabolic adaptation.

Level 3: True Non-Response (Rare)

You've been at maximum dose for 16+ weeks, all treatable causes ruled out, and total weight loss is under 5%. This is where genetic factors (PAM variants, GLP1R variants) become the likely explanation.

The Decision Tree

Step 1: Are you at a therapeutic dose? If not → titrate up before concluding anything.

Step 2: Taking medication correctly? (For oral Wegovy: fasting, water limits, timing. For injectables: proper injection technique, rotation sites.)

Step 3: Check for interfering medications — corticosteroids, some antidepressants, insulin, beta-blockers.

Step 4: Get labs — TSH, A1C, lipase, kidney function, vitamin levels.

Step 5: Consider medication switch — semaglutide → tirzepatide (different mechanism), or vice versa.

Step 6: Genetic testing — PrecisionLife/Ovation tests when available, or discuss with an obesity medicine specialist.